| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 6,070,266 | 7,321,501 | ||
| Prepaid expenses and other current assets | 63,202 | 75,342 | ||
| Total current assets | 6,133,468 | 7,396,843 | ||
| Total assets | 6,133,468 | 7,396,843 | ||
| Accounts payable | 421,142 | 970,025 | ||
| Accrued expenses | 512,029 | 260,624 | ||
| Accrued series a convertible preferred payments payable | 1,829,610 | 1,715,711 | ||
| Warrant liability | 2,600 | 3,600 | ||
| Total current liabilities | 2,765,381 | 2,949,960 | ||
| Total liabilities | 2,765,381 | 2,949,960 | ||
| Common stock (par value 0.0001 per share, 7,000,000,000 and 250,000,000 shares authorized at september 30, 2025, and december 31, 2024, respectively 42,284,502 and 421,124 shares issued and outstanding as of september 30, 2025, and december 31, 2024, respectively) | 4,228 | 4,228 | ||
| Additional paid-in capital | 114,322,129 | 114,478,202 | ||
| Accumulated deficit | -110,958,270 | -110,035,547 | ||
| Total stockholders' equity (deficit) | 3,368,087 | 4,446,883 | ||
| Total liabilities and stockholders' equity (deficit) | 6,133,468 | 7,396,843 | ||
Petros Pharmaceuticals, Inc. (PTPI)
Petros Pharmaceuticals, Inc. (PTPI)